Baseline characteristics

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors · Source last updated 2020-05-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      0

   2. group Id

      BG001

      value

      0

   3. group Id

      BG002

      value

      0

   units

   Participants

groups

1. description

   INCB001158 dosed at 50mg BID in combination with epacadostat (100 mg BID) and pembrolizumab (200 mg Q3W)

   id

   BG000

   title

   INCB001158 50mg BID+ Epacadostat + Pembrolizumab

2. description

   INCB001158 dosed at 75mg BID in combination with epacadostat (100 mg BID)and pembrolizumab (200 mg Q3W)

   id

   BG001

   title

   INCB001158 75 mg BID + Epacadostat + Pembrolizumab

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. title

   Age, Continuous

2. classes

   1. categories

      1. title

         Female

      2. title

         Male

   title

   Sex: Female, Male

   unit Of Measure

   participants

3. title

   Race/Ethnicity, Customized

   unit Of Measure

   participants

4. title

   Race/Ethnicity, Customized

   unit Of Measure

   participants

population Description

No patients were analyzed due to insufficient numbers and risk of identifying patient by reporting data on 1 person enrolled in cohort 2

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice